Go Deep
Noile-Immune Biotech Inc.
Noile-Immune Biotech Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 23,298 | -5.1 | 1.07 | 0.00 | 53.27 |
Noile-Immune Biotech Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 715,000.0 |
| Net Profit | -218,584,000.0 | -153,432,000.0 | -188,434,000.0 | -193,430,000.0 |
| EPS | — | -3.5 | — | — |
Noile-Immune Biotech Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 5,000,000.0 | 7,587,000.0 | 316,818,000.0 | 625,783,000.0 | — |
| Net Profit | -793,536,000.0 | -964,455,000.0 | -1,130,014,000.0 | -386,622,000.0 | — |
| EPS | -18.3 | -22.3 | -27.2 | -9.9 | — |
Noile-Immune Biotech Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 4,011,579,000.0 | 4,800,172,000.0 | 5,778,946,000.0 | 4,641,032,000.0 | — |
| Total Liabilities | 79,639,000.0 | 74,675,000.0 | 91,494,000.0 | 340,415,000.0 | — |
| Total Equity | 3,931,940,000.0 | 4,725,497,000.0 | 5,687,452,000.0 | 4,300,617,000.0 | — |
Owes vs Owns
Noile-Immune Biotech Inc. owed ¥0.02 for every ¥1 it owned in Jun 2026, down from ¥0.07 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.02× | 0.02× | 0.02× | 0.02× | 0.07× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Noile-Immune Biotech Inc. Assets & Liabilities Breakdown (JPY millions)
What it owns — Dec 2025
Cash & short-term investments 97.7%Other assets 2.3%
How it's funded — Dec 2025
Other liabilities 1.6%Shareholders' equity 98.0%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 3,918.3 | 4,670.9 | 5,555.7 | 4,521.0 |
| Receivables | 0.0 | 15.6 | 0.0 | 0.0 |
| Inventory | 2.2 | 8.6 | 20.9 | 3.9 |
| Fixed assets (tangible) | 0.0 | 0.0 | 0.0 | 0.0 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 91.1 | 105.1 | 202.4 | 116.1 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Payables | 16.1 | 8.5 | 18.7 | 217.8 |
| Other liabilities | 63.5 | 66.2 | 72.8 | 122.6 |
| Shareholders' equity | 3,931.9 | 4,725.5 | 5,687.5 | 4,300.6 |
| Net tangible assets | 3,931.9 | 4,725.5 | 5,687.5 | 4,300.6 |
Noile-Immune Biotech Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -752,219,000.0 | -887,809,000.0 | -873,076,000.0 | -107,176,000.0 | — |
| Investing Activities | -378,000.0 | 557,000.0 | -5,316,000.0 | 0.0 | — |
| Financing Activities | -20,000.0 | 2,500,000.0 | 1,913,086,000.0 | 487,615,000.0 | — |